Blockchain Registration Transaction Record

GeoVax Advances Mpox/Smallpox Vaccine Toward Phase 3 Trial in 2026

GeoVax Labs announces Phase 3 trial plans for GEO-MVA mpox/smallpox vaccine in 2026, addressing global supply constraints with accelerated regulatory pathway and manufacturing readiness.

This development matters because it addresses a critical gap in global vaccine supply for orthopoxviruses like mpox and smallpox, which pose ongoing public health threats. Recent outbreaks have depleted government stockpiles, highlighting vulnerabilities in pandemic preparedness. GEO-MVA's accelerated regulatory pathway could provide a much-needed domestic manufacturing alternative, reducing reliance on single foreign sources and enhancing biosecurity. For populations at risk—including healthcare workers, immunocompromised individuals, and those in outbreak regions—this vaccine represents a potential safeguard against future epidemics. Furthermore, successful development would strengthen global health infrastructure, offering a tool for rapid response to emerging viral strains and supporting international preparedness frameworks.